Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Famciclovir Articles

MORE ON NETIVUDINE WITHDRAWAL

4 April 1994

WELLCOME'S SHARE PRICE WOES

4 April 1994

EUROPEAN STOCK COMMENT

28 March 1994

WELLCOME BOTTOMING OUT; IMPROVEMENT AHEAD

28 February 1994

ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES

31 January 1994

WINNERS AND LOSERS IN GLOBAL PHARMA INDUSTRY

31 January 1994

EUROPEAN STOCK COMMENT

24 January 1994

1ST FAMVIR LAUNCH SPARKS WELLCOME PRICE CUT

24 January 1994

WELLCOME "TOO FOCUSED" FOR INDEPENDENCE

24 January 1994

EUROPEAN STOCK COMMENT

20 December 1993

FAMCICLOVIR APPROVED IN ITS FIRST MARKET

20 December 1993

WORLD MARKET FOR ANTI-INFECTIVES

15 November 1993

ZOVIRAX PERFORMANCE: A WORRY FOR WELLCOME?

8 November 1993

WELLCOME RESULTS AS EXPECTED BUT US SLOWER

1 November 1993

ANTIVIRAL CLASH LOOMS AS ICAAC DATA PRESENTED

25 October 1993

EUROPEAN STOCK COMMENT

25 October 1993

EUROPEAN STOCK COMMENT

11 October 1993

CLINICAL DATA PRESENTED ON FAMCICLOVIR

4 October 1993

EUROPEAN STOCK COMMENT

4 October 1993

ADAPTING TO A CHANGING DRUG IND ENVIRONMENT

20 September 1993

EUROPEAN STOCK COMMENT

6 September 1993

FAMCICLOVIR NEARING MARKET

26 July 1993

FAMICICLOVIR AS EFFECTIVE AS ZOVIRAX

24 May 1993

ADAPTING TO HEALTH CARE REFORM THE SB WAY

17 May 1993

ACICLOVIR VERSUS PENCICLOVIR

10 May 1993

DRUG FIRMS TO WORK TOGETHER ON AIDS R&D

26 April 1993

SMITHKLINE BEECHAM "EXCELLENT PROGRESS"

26 April 1993

LONDON STOCK COMMENT

12 April 1993

Showing 101-128 of 128 articles

Go to beginningPrevious
  • 1
  • 2
NextGo to end
  • Hot Topics
  • Most Read
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS